阿兹海默症市场：KOL 洞察

本报告考察了全球阿兹海默症市场，并提供了市场概述，包括已上市的治疗方法、管道趋势和未来前景。

目录

执行摘要

目前与未来的治疗演算法

研究目的

最近核准的治疗方法

• 抗淀粉样蛋白 BETA (A-BETA) 单株抗体 (mAb)
  • 主要见解摘要
  • Aduhelm（Aducanumab、Biogen/神经免疫疗法）
  • Rekenbi（recanemab；BioArctic/Eisai/Biogen）

管道产品

• 抗淀粉样蛋白 BETA (A-BETA) 单株抗体
• BETA淀粉样蛋白抑制剂/GABA A 受体激动剂
• 胜肽水解酶抑制剂
• 毒蕈碱受体调节剂/sigma-1受体激动剂
• 微丝蛋白调节剂
• 肝细胞生长因子刺激剂
• 毒蕈碱 (M1/M4) 受体药物
• 突触核蛋白抑制剂/tau 蛋白抑制剂
• IL23、IL6抑制剂/MAPK3/MAPK1抑制剂/NF-KB抑制剂/TNF抑制剂
• 胰高血糖素样胜肽1受体激动剂
• 5型环核甘酸磷酸二酯酶抑制剂
• 乙酰胆碱酯酶抑制剂/烟碱受体调节剂
• 5-HT1 5-羟色胺受体激动剂/褪黑素受体激动剂/5-羟色胺1D/2B受体激动剂

早期展望

• 主要见解摘要
  • ABBV 916（BETA 淀粉样蛋白抑制剂；AbbVie）
  • ACI 24（抗 ABETA 疫苗，AC 免疫）
  • ACI 35.030（脂质体抗 pTau 疫苗；AC Immune/Janssen Pharmaceuticals）
  • AEF 0217（大麻素受体 CB1 拮抗剂；Aelis Farma）
  • AL-002（TREM2 蛋白刺激剂；Alector）
  • ALN APP（RNA 干扰，Alnylam Pharmaceuticals）
  • AV 1959D（基于 DNA 的抗原决定位疫苗，Capo Therapeutics）
  • Beplanemab（tau 蛋白抑制剂；UCB Biopharma/Roche）
  • BIIB 080（IONIS-MAPTRX/反义 tau 蛋白抑制剂；Biogen/Ionis Pharmaceuticals）
  • Elcubragistat（单酰基甘油脂肪酶抑制剂；Abide Therapeutics/Lundbeck A/S）
  • Pepinemab（CD100 抗原抑制剂，Vaccinex）
  • Valoglutamstat；（麸酰胺酸肽环转移酶抑制剂；Vivoryon Therapeutics）
  • Contraloid（BETA淀粉样蛋白抑制剂；Priavoid）
  • PRX012（抗 A-BETA抗体，Prothena）
  • Semolinemab（抗 tau 抗体；AC Immune/Roche）
  • Teltomotide（端粒酶胜肽疫苗；Pharmaxa/KAEL-GemVax/Samsung Pharm）

附录

While KOLs say BioArctic/Biogen/Eisai's Leqembi is set to dominate AD therapy, what are the dosing, cost and reimbursement challenges that could impact takeup? Eli Lilly's next-generation late-stage anti-amyloid therapy donanemab is eagerly anticipated, but what clinical advantages and challenges do experts identify, and how might it impact Leqembi? KOLs critically assess the prospects of launched and pipeline therapies.

In addition to the full report, licensed users can access the following KOL Bulletins via the Attachments area.

Key questions answered:

• Biogen's Aduhelm was seen as a trailblazer in AD therapy but has failed to live up to expectations - how do KOLs assess the failure?
• How might Eli Lilly's remternetug offer better patient convenience and the possibility of home-based administration?
• How do KOLs assess the potential of Roche's innovative Brainshuttle approach for trontinemab?
• Tau remains an attractive target, so why are KOLs sceptical about the prospects for Annovis Bio's Posiphen and TauRx's LMTX?
• How do KOLs assess pipeline therapies which do not target amyloid and tau pathways, such as AlphaCognition's Alpha 1062, AriBio's AR 1001, Karuna Therapeutics' KarXT and BioVie's NE3107?
• Why is KOL opinion split on the prospects for Alzheon's niche pipeline therapy valiltramiprosate?

Key brands covered in this report:

Table of Contents

Executive summary (6)

Current and future treatment algorithm

Research objectives (2)

Recently approved therapies (19)

• Anti-amyloid beta (A-Beta) monoclonal antibodies (mAbs) (19)
  • Key insights summary (2)
  • Aduhelm (aducanumab; Biogen/Neurimmune Therapeutics) (1)
  • Leqembi (lecanemab; BioArctic/Eisai/Biogen) (16)

Pipeline products (104)

• Anti-amyloid beta (A-Beta) mAbs (19)
  • Key insights summary (2)
  • LY 3002813 (donanemab; Eli Lilly & Co.) (1)
  • LY-3372993 (remternetug; Eli Lilly & Co.) (1)
  • RG-6102 (trontinemab; Roche) (15)
• Amyloid beta-protein inhibitors/GABA A receptor agonists (7)
  • ALZ 801 (valiltramiprosate; BELLUS Health/FB Health/Alzheon) (7)
• Peptide hydrolase inhibitors (6)
  • COR-388 (atuzaginstat; Lighthouse Pharmaceuticals) (6)
• Muscarinic receptor modulators/Sigma-1 receptor agonists (6)
  • Blarcamesine (Anavex Life Sciences) (6)
• Microfilament protein modulators (6)
  • Filora (simufilam; Cassava Sciences) (6)
• Hepatocyte growth factor stimulants (8)
  • Fosgonimeton (Athira Pharma) (8)
• Muscarinic (M1/M4) receptor agents (7)
  • KarXT (trospium chloride/xanomeline; Karuna Therapeutics [BMS]) (7)
• Synuclein inhibitors/Tau protein inhibitors (10)
  • Key insights summary (2)
  • LMTX (hydromethylthionine mesylate; TauRx Pharmaceuticals) (1)
  • Posiphen (buntanetap; Annovis Bio) (7)
• IL23, IL6 inhibitors/MAPK3/MAPK1 inhibitors/NF-kB inhibitors/TNF inhibitors (9)
  • NE3107 (BioVie) (9)
• Glucagon-like peptide 1 receptor agonists (8)
  • Rybelsus (semaglutide oral; Novo Nordisk) (8)
• Type 5 cyclic nucleotide phosphodiesterase inhibitors (4)
  • AR 1001 (AriBio) (4)
• Acetylcholinesterase inhibitors/Nicotinic receptor modulators (7)
  • Alpha 1062 (benzgalantamine; AlphaCognition) (7)
• 5-HT1 serotonin receptor agonists/Melatonin receptor agonists/Serotonin 1D/2B receptor agonists (7)
  • Neu-P11 (piromelatine; Neurim Pharmaceuticals) (7)

Early-stage prospects (21)

• Key insights summary (21)
  • ABBV 916 (amyloid beta-protein inhibitor; AbbVie) (1)
  • ACI 24 (anti-Abeta vaccine; AC Immune) (1)
  • ACI 35.030 (liposomal anti-pTau vaccine; AC Immune/ Janssen Pharmaceuticals) (1)
  • AEF 0217 (cannabinoid receptor CB1 antagonist; Aelis Farma (1)
  • AL-002 (TREM2 protein-stimulant; Alector) (1)
  • ALN APP (RNA interference; Alnylam Pharmaceuticals) (1)
  • AV 1959D (DNA based epitope vaccine; Capo Therapeutics) (1)
  • Bepranemab (Tau protein inhibitor; UCB Biopharma/Roche) (1)
  • BIIB 080 (IONIS-MAPTRX/antisense Tau protein inhibitor; Biogen/Ionis Pharmaceuticals) (1)
  • Elcubragistat (monoacylglycerol lipase inhibitor; Abide Therapeutics/Lundbeck A/S) (1)
  • Pepinemab (CD100 antigen inhibitors; Vaccinex) (1)
  • Varoglutamstat; (glutaminyl-peptide cyclotransferase inhibitor; Vivoryon Therapeutics) (1)
  • Contraloid (amyloid beta-protein inhibitor; Priavoid) (1)
  • PRX012 (anti-A-Beta antibody; Prothena) (1)
  • Semorinemab (anti-tau antibody; AC Immune/Roche) (1)
  • Tertomotide (telomerase peptide vaccine; Pharmexa/KAEL-GemVax/Samsung Pharm) (4)

Appendix (5)

• KOL details (5)
  • KOLs from North America (1)
  • KOLs from Europe (3)